This week in drug discovery (27 February – 3 March)

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. 

As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a number of developments in cancer drug discovery this week. Most notably, a 20-year mystery regarding the ‘dark matter’ of the genome has been solved and researchers have announced preclinical success in treating ovarian cancer with CAR-T therapy.  

The top stories: 

Prostate cancer combination therapy reduces risk of death 

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations. 

Epigenetics discovery could lead to new class of cancer drugs 

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. 

Partners from UK and Singapore agree cancer drug discovery deal 

Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients. 

CAR-T cell therapy holds promise for ovarian cancer 

CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer. The study authors hope that the discovery will pave the way for a clinical trial to see how effective the treatment is for women with the disease. 

Partnership will develop targeted miRNAs to treat pancreatic cancer 

SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free